DAIC

APRIL 12, 2024

Getty Images milla1cf Fri, 04/12/2024 - 20:55 April 12, 2024 — Simpson Interventions, Inc. , This designation recognizes the transformative potential of our technology in addressing a critical unmet need in the treatment of patients with coronary chronic total occlusions. Food and Drug Administration ( FDA ).

Technology 111

Technology Cardiovascular Interventions Coronary Artery Disease Innovation 111

Circulation: Cardiovascular Interventions

JANUARY 23, 2024

Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Current metrics used to adjust for case mix complexity in congenital cardiac catheterization are becoming outdated due to the introduction of novel procedures, innovative technologies, and expanding patient subgroups.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Heart Disease Pediatrics 40

ADN Center of Excellence

JANUARY 14, 2024

One of the defining moments of the training was the hands-on experience with state-of-the-art Abbott device, empowering attendees to master the latest technologies in cardiovascular care. The palpable excitement in the room as doctors interacted with these innovative tools underscored the practical significance of our training.

Bicuspid/Mitral 59

Bicuspid/Mitral Anatomy Education Heart Valves 59

ADN Center of Excellence

JANUARY 14, 2024

One of the defining moments of the training was the hands-on experience with state-of-the-art Abbott device, empowering attendees to master the latest technologies in cardiovascular care. The palpable excitement in the room as doctors interacted with these innovative tools underscored the practical significance of our training.

Bicuspid/Mitral 52

Bicuspid/Mitral Anatomy Education Heart Valves 52

DAIC

APRIL 5, 2024

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets. Cardiovascular intervention is one of the fastest-growing global medtech markets, with significant unmet patient need.

Cardiovascular Interventions 105

Cardiovascular Interventions Technology Innovation Angina 105

DAIC

MAY 31, 2024

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.

Peripheral Arterial Disease 104

Peripheral Arterial Disease Innovation Coronary Artery Disease Cardiovascular Interventions 104

Cardiometabolic Health Congress

JULY 17, 2024

February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59